Pembrolizumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]

  • In development
  • GID-TA11694
  • Expected publication date: 

Documents

Documents created during the development process.

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6607

Notes